PCI Biotech - Fundamentale forhold (PCIB)

Logdec · mai 21, 2023, 10:30am

Ny patentsøknad av Anders og Pål

Offentlig 04.05.2023

The present invention concerns a method of generating an immune response to bacteria in a subject, in which live bacteria (such as BCG) and a photosensitizing agent are administered to cells of the subject and the cells are irradiated with light of a wavelength effective to activate the photosensitizing agent to generate an immune response to the bacteria. Pharmaceutical compositions, products and kits for this purpose are also provided.

https://worldwide.espacenet.com/patent/search/family/078806113/publication/WO2023073116A1?q=pn%3DWO2023073116A1

Kaizers · mai 23, 2023, 8:44pm

Spennende at PCIB skal delta på messe i USA.
BIO International 2023, Boston, US, 5-8 June 2023.

Hva kan vi forvente av PCIB fremover?
Har folk tro på den nye strategien til PCIB?

TekBot · mai 24, 2023, 8:43am

Disclosure of voting rights for Chairman of the Board

Oslo, 24 May 2023. PCI Biotech Holding ASA (“PCI Biotech” or the “Company”)
issue this notification on behalf of its chairman, Hans Peter Bøhn.

…

Vis børsmeldingen

Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general
meeting of the Company on 25 May 2023. Mr. Bøhn holds 123,662 shares,
representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has
received powers of attorney to represent and vote for 5,590,554 additional
shares. In total, Mr. Bøhn will represent and vote for 15.3 per cent of the
share capital. A major part of the powers of attorney are without voting
instructions. The powers of attorney are only valid at the annual general
meeting on 25 May 2023.

This information is subject to the disclosure requirements pursuant to section
4 -3, cf. section 5-12 of the Norwegian Securities Trading Act.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757

Kilde

TekBot · mai 25, 2023, 9:40am

Minutes from Annual General Meeting 2023

Tekspert · juni 1, 2023, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@StockDZ (24 likes)

@Kaizers (19 likes)

@Oxion (18 likes)

Resten av topp 10:

@laplagam (17 likes)
@Logdec (14 likes)
@Amatouren (13 likes)
@Mitra (8 likes)
@NJR (7 likes)
@Ruben2 (6 likes)
@urban66 (3 likes)

Gratulerer!

Tekspert · juli 1, 2023, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Kaizers (49 likes)

@StockDZ (24 likes)

@Buffet (23 likes)

Resten av topp 10:

@Oxion (21 likes)
@laplagam (14 likes)
@ufo (10 likes)
@rockpus (8 likes)
@NJR (7 likes)
@Ruben2 (7 likes)
@olafalo (7 likes)

Gratulerer!

TekBot · august 25, 2023, 12:31pm

PCI Biotech: Invitation to first half interim 2023 results presentation

Oslo, Norway, 25 August 2023 - PCI Biotech (OSE: PCIB) invites to a webcast
presentation of the company’s first half 2023 interim report on Thursday 31
August 2023, 08:30am - 09:30am CEST (local time).
…

Vis børsmeldingen

The presentation will be held as a live webcast and can be accessed through
www.pcibiotech.com. There will be a Q&A session at the end of the presentation
and it will be possible to post written questions through the webcast console.

The company will be represented by Ronny Skuggedal (CEO/CFO), Anders Høgset
(CSO), and Morten Luhr (BD Manager), and the presentation will be held in
Norwegian.

The interim report and presentation will be made available on www.newsweb.no and
on the company’s webpage, www.pcibiotech.com, from 07.00am CEST the same day.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies and new technologies through its innovative
photochemical internalisation (PCI) technology platform. PCI induces triggered
endosomal release that is used to unlock the true potential of therapeutic
modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within bioprocessing and dermatology, well suited to
the specific strengths of the PCI technology. The fimaVACC programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors.

For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · august 31, 2023, 5:01am

PCI Biotech first half 2023 interim results

Oslo (Norway), 31 August 2023 - PCI Biotech (OSE: PCIB), today announces its
interim first half 2023 results. Please find enclosed the report and
presentation.
…

Vis børsmeldingen

Highlights review

fimaNAc - bioprocessing
The bioprocessing program for use of fimaNAc in gene therapy manufacturing has
generated new results that add to the initial patent application filed in
2H 2022. Continued focus on generating results that can trigger field testing
with potential customers to get feedback and develop a competitive technology.

fimaNAc - dermatology
For dermatology the study to demonstrate topical fimaNAc-mediated nucleic acid
delivery in a preclinical wound model is completed. The study demonstrated
significant delivery in a simplified model, but these results were not
translatable into the selected full-scale model when testing topical delivery of
unprotected (“naked”) nucleic acid, which is a challenging approach.

PCI Biotech will evaluate these initial results for the project and assess the
collaborative landscape for fimaNAc in dermatology.

fimaVacc - intratumoural immunotherapy
For fimaVacc we are exploring approaches aimed at identifying novel
immunotherapy treatment combinations, and a patent application for an
undisclosed treatment approach was filed in 1H 2023.

Corporate
The cash position of NOK 45 million enables a financial runway towards the end
of 2024 with current plans.

Ronny Skuggedal, CEO of PCI Biotech, comments: “We have seen promising early
signs of enhanced delivery of nucleic acids for dermatology in simplified
preclinical settings, but we were unfortunately not able to translate these
promising results at our first attempt in a relevant and challenging skin model.
The bioprocessing program has made good progress since the first patent
application was filed in 2H 2022. We continue to pursue external feedback, by
seeking field testing in collaboration with potential future customers.”

PCI Biotech will focus resources on research and development. Hence, moving
forward, PCI Biotech will report financial results on a half yearly basis, per
June 30 and December 31. We will continue to update our shareholders on a
regular basis, including updates on financial information. An updated financial
calendar will be announced shortly.

A live webcast in Norwegian will be held today, 31 August 2023, at 08:30am -
09:30am CEST (local time).

The presentation can be followed as a live webcast, accessed through the link
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230831_1 or the
company’s website under “Investors - Reports and presentations - Webcasts”.

There will be a Q&A session at the end of the presentation and it will be
possible to post written questions through the webcast console.

The interim report and the presentation will also be available on www.newsweb.no
and on the company’s webpage, www.pcibiotech.com from 07:00am (CEST) today.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies and new technologies through its innovative
photochemical internalisation (PCI) technology platform. PCI induces triggered
endosomal release that is used to unlock the true potential of therapeutic
modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within dermatology and bioprocessing, well suited to
the specific strengths of the PCI technology. The fimaVacc programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors. For further
information, please visit: www.pcibiotech.co

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

TekBot · august 31, 2023, 8:27am

Financial calendar

TekBot · september 1, 2023, 9:04am

PCI Biotech: Write-down of share capital registered

Oslo, Norway, 1 September 2023 - PCI Biotech Holding ASA (OSE: PCIB) Reference
is made to the resolution made by the Annual General Meeting 25 May 2023, in
respect of a write-down of share capital by reducing the par value of PCI
…

Vis børsmeldingen

Biotech Holding ASA’s shares from NOK 3.00 to NOK 0.03.

Parts of the share capital reduction amount shall be used to cover loss that
cannot be covered in any other way and the residual of the reduction amount
shall be transferred to other equity.

The capital reduction was registered in the Norwegian Register of Business
Enterprises on 16(th) August 2023, and the transaction has thus been completed.

The share capital is now NOK 1,119,791.70, divided into 37,326,390 shares, each
with a nominal value of NOK 0.03.

Contact information:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
www.pcibiotech.com

Kilde

TekBot · september 4, 2023, 8:14am

PCI Biotech: Employee share option scheme

Oslo, 4 September 2023 - PCI Biotech (OSE: PCIB), today announce that the Board
of Directors has granted share options to key employees.

…

Vis børsmeldingen

In accordance with the authorisation granted by the Annual General Meeting 25
May 2023 and the remuneration policy adopted by the Annual General Meeting 28
May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has
awarded a total of 700,000 share options to key employees. Each share option
gives the right to subscribe for or acquire one share per option (after PCI
Biotech’s choice), at a strike price of NOK 1.66, equal to the volume weighted
average share price (VWAP) for the last 5 days of trade prior to the grant date.
The share options are granted without consideration and are subject to service-
based vesting conditions, and the share options will vest equally over a three-
year vesting term. The share options are lapsing in Q3 2028. Further details
about the share option program are described in PCI Biotech’s remuneration
policy.

According to the remuneration policy the BoD will at allotment of share options
seek to allot a number of share options with a total fair value, calculated
according to the Black-Scholes model, that is partly linked to the annual base
salary for each individual. Other elements that will be assessed in the
allotment are the balance between total short- and long-term performance-based
rewards, current value of share options held, overall performance, work
responsibility, importance of retention and position.

The number of share options granted is based on these guidelines and in
addition, the share options are granted with a value cap of 20 times the strike
price. If this value cap threshold is met all share options will vest
immediately and be available for exercise.

To ensure long-term ownership by executive management, shares obtained by
exercise of share options shall be held for at least one year, except shares to
be sold immediately to cover transaction costs and tax under a so-called cash-
less exercise. Through the long-term incentive program the board expects members
of the executive team to build up and maintain share ownership with a market
value equal to at least one-year gross base salary, before any shares may be
sold.

Of the 700,000 share options, 440,000 share options were allotted to the
following primary insiders:

300,000 share options were allotted to Ronny Skuggedal, CEO. After the
allotment, Ronny Skuggedal holds a total portfolio of 660,000 unexercised share
options and 55,000 shares.

120,000 share options were allotted to Anders Høgset, CSO. After the allotment,
Anders Høgset holds a total portfolio of 370,000 unexercised share options and
64,800 shares.

20,000 share options were allotted to Kristin Eivindvik, CDO. After the
allotment, Kristin Eivindvik holds a total portfolio of 130,000 unexercised
share options and 25,200 shares.

Primary insider notifications pursuant to the market abuse regulation article
19 are attached.

The current authorisation, as of 25 May 2023, allows for a total of 2,790,000
share options, of which 1,700,000 now have been granted by the Board of
Directors.

For more information, please contact:
Ronny Skuggedal, CEO, rs(a)pcibiotech.no, Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and to section 5-12 of the Norwegian
Securities Trading Act.

Kilde

olafalo · september 5, 2023, 12:00pm

…pathophysiological barriers that hamper its target reach, which is the cytosol, and execution of gene silencing action. siRNA therapeutics: insights, challenges, remedies and future prospects. Published online: 29 Aug 2023. Expert Opinion on Drug Delivery.

Despite the advantages of using mRNA in cancer therapeutics, challenging biological barriers encountered following systemic administration remain major obstacles to its clinical application. mRNA: A promising platform for cancer immunotherapy. Advanced Drug Delivery Reviews Volume 199, August 2023.

Buffet · september 6, 2023, 7:23am

Er det en emisjon med en fryktelig lav kurs som ligger på tegnebordet nå om dagene?

TekBot · september 7, 2023, 10:37am

PCI Biotech: European patent for mRNA delivery with fimaNAc

Oslo (Norway), 7 September 2023 - PCI Biotech (OSE: PCIB), a biopharmaceutical
company, today announces that the European Patent Office (EPO) has informed PCI
Biotech that they intend to grant a new patent covering delivery of mRNA by use
…

Vis børsmeldingen

of PCI Biotech’s fimaNAc technology. This application is primarily foreseen to
be used for dermatology.

Nucleic acid therapeutics, including mRNAs, have the potential to improve the
treatment of dermatological diseases, but delivery to skin lesions remains an
obstacle. This is a challenge PCI Biotech’s fimaNAc technology is uniquely
positioned to solve, by light-directed intracellular nucleic acid delivery.

The European patent secures protection until 2039 and this patent application is
pending in the US and key Asian markets.

About PCI Biotech
PCI Biotech is a biopharmaceutical company focussing on development and
commercialisation of novel therapies and new technologies through its innovative
photochemical internalisation (PCI) technology platform. PCI induces triggered
endosomal release that is used to unlock the true potential of therapeutic
modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for
intracellular delivery of nucleic acids. The technology can be used for most
types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids
to viral vectors. The development of the fimaNAc programme is currently focussed
on selected applications within dermatology and bioprocessing, well suited to
the specific strengths of the PCI technology. The fimaVacc programme aims to
enhance immunotherapy in cancer, by triggered endosomal release of antigens or
nucleic acids encoding antigens, or immunostimulatory factors. For further
information, please visit: www.pcibiotech.com

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo.
Ronny Skuggedal, CEO, rs@pcibiotech.no mobile: +47 9400 5757.

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

Kilde

Kaizers · september 7, 2023, 11:52am

Herlig nyhet! Nå kommer oppturen

polygon · september 7, 2023, 12:11pm

Når det dukker opp noen eksterne som vil forsøke å benytte seg av PCI for levering av mRNA? For det de prøvde internt fungerte altså ikke.

Edit: trodde du skrev «Når kommer oppturen?»

rockpus · september 7, 2023, 12:08pm

Et patent gir vel på ingen måte noen garanti for kommersiell interesse?

Kaizers · september 7, 2023, 12:26pm

De skal være med å bidra inn mot industrien.
Patent til 2039 og finansiering ut 2024 gi ro.
2-3 andre patenter i pipeline.

Pluss får de i USA og Asia kan PCIB igjen lukte på 10kr.

rockpus · september 7, 2023, 12:32pm

Poenget er at det er vel ikke manglende grad av patenter som er årsaken til at PCIB så langt har møtt veggen?
At noe lar seg patentere, betyr ikke at det automatisk lar seg selge.
Kun ment som et lite tankekors til de som eventuelt hiver seg på kurstoppen i dag…

pdx · september 8, 2023, 9:57am

Fortsett småpraten i småprat plis